1,25-dihydroxyvitamin D hypercalcemia and imatinib hepatotoxicity in a patient with GIST

Article Type

Changed

Fri, 01/04/2019 - 11:13

Display Headline

Author(s)

Hypercalcemia is commonly encountered in carcinomas, most commonly in breast and lung cancers, but is also encountered in some hematologic malignancies such as multiple myeloma, leukemia, and lymphoma. Hypercalcemia occurs in 20%-30% of carcinomas during their course and usually portends a poor prognosis.¹ It occurs in malignancy predominantly due to 2 mechanisms. The first mechanism is parathyroid hormone-related protein (PTHrP) and osteolytic bone metastasis. Hypercalcemia mediated by PTHrP release by the tumor is commonly called humoral hypercalcemia.

Click on the PDF icon at the top of this introduction to read the full article.

Article PDF

JCSO_Aug_363_Skubitz.pdf

Issue

The Journal of Community and Supportive Oncology - 14(8)

Publications

The Journal of Community and Supportive Oncology

MDedge Hematology and Oncology

Topics

Patient & Survivor Care

Page Number

363-366

Legacy Keywords

1,25-dihydroxyvitamin D, vitamin D, hypercalcemia, imatinib hepatotoxicity, gastrointestinal stromal tumors, GIST

Sections

Case Reports

Author(s)

Drew Oostra et al

Author(s)

Drew Oostra et al

Article PDF

JCSO_Aug_363_Skubitz.pdf

Article PDF

JCSO_Aug_363_Skubitz.pdf

Hypercalcemia is commonly encountered in carcinomas, most commonly in breast and lung cancers, but is also encountered in some hematologic malignancies such as multiple myeloma, leukemia, and lymphoma. Hypercalcemia occurs in 20%-30% of carcinomas during their course and usually portends a poor prognosis.¹ It occurs in malignancy predominantly due to 2 mechanisms. The first mechanism is parathyroid hormone-related protein (PTHrP) and osteolytic bone metastasis. Hypercalcemia mediated by PTHrP release by the tumor is commonly called humoral hypercalcemia.

Click on the PDF icon at the top of this introduction to read the full article.

Hypercalcemia is commonly encountered in carcinomas, most commonly in breast and lung cancers, but is also encountered in some hematologic malignancies such as multiple myeloma, leukemia, and lymphoma. Hypercalcemia occurs in 20%-30% of carcinomas during their course and usually portends a poor prognosis.¹ It occurs in malignancy predominantly due to 2 mechanisms. The first mechanism is parathyroid hormone-related protein (PTHrP) and osteolytic bone metastasis. Hypercalcemia mediated by PTHrP release by the tumor is commonly called humoral hypercalcemia.

Click on the PDF icon at the top of this introduction to read the full article.

Issue

The Journal of Community and Supportive Oncology - 14(8)

Issue

The Journal of Community and Supportive Oncology - 14(8)

Page Number

363-366

Page Number

363-366

Publications

The Journal of Community and Supportive Oncology

MDedge Hematology and Oncology